Cargando…

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

BACKGROUND: Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease. The purpose of the present study was to investigate the efficacy of amantadine in Parkinson's disease patients suffering from dyskinesias. METHODS: In this m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawada, Hideyuki, Oeda, Tomoko, Kuno, Sadako, Nomoto, Masahiro, Yamamoto, Kenji, Yamamoto, Mitsutoshi, Hisanaga, Kinya, Kawamura, Takashi
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013111/ https://www.ncbi.nlm.nih.gov/pubmed/21217832 http://dx.doi.org/10.1371/journal.pone.0015298

Ejemplares similares

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study
por: Sawada, Hideyuki, et al.
Publicado: (2013)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Diagnostic Accuracy of Apparent Diffusion Coefficient and (123)I-Metaiodobenzylguanidine for Differentiation of Multiple System Atrophy and Parkinson’s Disease
por: Umemura, Atsushi, et al.
Publicado: (2013)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP)
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease
por: Sawada, Hideyuki, et al.
Publicado: (2015)

Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease
por: Umemura, Atsushi, et al.
Publicado: (2015)

Video-fluoroscopic swallowing study scale for predicting aspiration pneumonia in Parkinson’s disease
por: Tomita, Satoshi, et al.
Publicado: (2018)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
por: Fan, Qian-Ya, et al.
Publicado: (2022)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
por: Sawada, Hideyuki, et al.
Publicado: (2014)

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
por: Elmer, Lawrence W., et al.
Publicado: (2018)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
por: Oertel, Wolfgang, et al.
Publicado: (2017)

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2021)

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease
por: Whone, Alan, et al.
Publicado: (2019)

Clinical Factors Associated with Abnormal Postures in Parkinson's Disease
por: Oeda, Tomoko, et al.
Publicado: (2013)

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2020)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
por: Hauser, Robert A., et al.
Publicado: (2021)

Correction: Clinical Factors Associated with Abnormal Postures in Parkinson's Disease
por: Oeda, Tomoko, et al.
Publicado: (2013)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years
por: Sawada, Hideyuki, et al.
Publicado: (2018)

A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
por: Yoshikawa, Norishige, et al.
Publicado: (2015)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial
por: Nomura, Takashi, et al.
Publicado: (2021)

Blood pressure fluctuation and hypertension in patients with Parkinson's disease
por: Tsukamoto, Tetsuro, et al.
Publicado: (2013)

Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2022)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Amantadine-Induced Patulous Eustachian Tubes in Parkinson's Disease
por: Boyd, J. T., et al.
Publicado: (2013)

Randomized trial of granulocyte colony-stimulating factor for spinal cord injury
por: Koda, Masao, et al.
Publicado: (2021)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Delirium and High Fever Are Associated with Subacute Motor Deterioration in Parkinson Disease: A Nested Case-Control Study
por: Umemura, Atsushi, et al.
Publicado: (2014)

Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial
por: Hanai, Akiko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hjhpgogj1dhim8eqcqnevg6jp3